Trial Profile
An Open-Label, Multicenter, Randomized Phase II Trial Comparing the Efficacy, Safety, and Pharmacokinetics of GA101 1000 mg Versus 2000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms GAGE
- Sponsors Genentech
- 13 Jul 2016 Status changed from active, no longer recruiting to completed.
- 15 Oct 2015 Results published in the Blood
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.